Literature DB >> 33604726

Regarding: A global anti-B cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome.

Alan Majeranowski1, Marcin Okrój2.   

Abstract

Entities:  

Year:  2021        PMID: 33604726     DOI: 10.1007/s00467-021-04981-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  1 in total

1.  Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.

Authors:  Rabih Said; Apostolia M Tsimberidou
Journal:  Expert Opin Biol Ther       Date:  2017-09-11       Impact factor: 4.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.